Diffusion Weighted Magnetic Resonance Imaging for Preoperative Staging in Gastric Adenocarcinoma Patients
Use of Diffusion Weighted Magnetic Resonance Imaging to Stage Gastric Adenocarcinoma Patients Preoperatively
Preoperative staging for gastric adenocarcinoma is an important procedure to detect advanced disease stateS for the patients in which the surgery may be unnecessary to perform. Although there are many imaging techniques for this purpose, sensitivity and specificity of these techniques still remains to be low.Preoperative detection of peritoneal carcinomatosis and involvement of lymph nodes beyond D2 may prevent surgical procedures.
Removal of the determined lymph nodes according to the type of the surgery is the accepted surgical method. However, accurate determination of malignant lymph nodes may prevent dissection of some groups of the lymph nodes. These findings may cause a new definition of gastric lymph node dissection.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
- proven endoscopic diagnosis of gastric adenocarcinoma
- for staging purposes, computed tomography for all patients
- evaluation of benign and malignant lymph nodes according to computed tomography findings and mapping of the lymph nodes
- to state precisely resectable patients according to computed tomography and anesthetic evaluation
- evaluation of benign and malignant lymph nodes according to diffusion weighted magnetic resonance imaging findings and mapping of the lymph nodes
- standard gastrectomy and D2 lymph node dissection
- mapping of the lymph nodes after taking the specimen out
- histopathological diagnosis of the lymph nodes and mapping
- comparison of the results taken from computed tomography, diffusion weighted magnetic resonance imaging and histopathological analysis
Studietyp
Inskrivning (Faktisk)
Fas
- Tidig fas 1
Kontakter och platser
Studieorter
-
-
-
Istanbul, Kalkon, 34093
- bezmialem vakif university faculty of medicine dept of general surgery
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- gastric adenocarcinoma proven by endoscopic biopsy;
- application of both computed tomography and diffusion weighted magnetic resonance imaging;
- standard gastrectomy and a D2 lymph node dissection;
- desire to attend the study protocol
Exclusion Criteria:
- preoperative neoadjuvant therapy;
- metastatic disease;
- undesired reaction to attend the study protocol
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Diagnostisk
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: diffusion MRI
histopathology of lymph nodes diagnosed by diffusion weighted magnetic resonance imaging
|
for diagnostic purposes, diffusion weighted magnetic resonance imaging in all patients
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
efficacy of diffusion weighted magnetic resonance imaging to detect benign and malignant lymph nodes
Tidsram: one year
|
to compare the radiologic diagnosis of benign and malignant lymph nodes with histopathological diagnosis
|
one year
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- DWMRIGASTADENO
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .